selected publications
-
academic article
- Metabolic Adaptations in Cancer and the Host Using Drosophila Models and Advanced Tools. CELLS. 1977-2003. 2024
- EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance.. CANCERS. 1-21. 2021
- Host-dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.. CANCER RESEARCH. 3862-3875. 2021
- Retinal Proteomics of a Mouse Model of Dystroglycanopathies Reveals Molecular Alterations in Photoreceptors.. JOURNAL OF PROTEOME RESEARCH. 3268-3277. 2021
- TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. SCIENCE SIGNALING. 1-15. 2021
- Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.. EMBO MOLECULAR MEDICINE. 1-18. 2021
-
congress communication
- Locating the alpha-dystroglycan O-mannosylglycosylation pathway in mouse retinal cells 2023
- Tumour heterogeneity and cell competition 2023
- First-line therapy based on kinase inhibitors and antibodies prevents resistance in EGFR-mutated lung cancer. . 1097-1097. 2022
- Synergy between kinase inhibitors and antibodies enables upfront prevention of recurring secondary resistance in EGFR-mutated lung cancer. 2021